Equity Issuances

AB Private Lending Fund issued 94,010 of common stock to feeder vehicles primarily created to hold the Fund’s Class I shares for $2,369,086.96.

“table details the shares sold: Date of Unregistered Sale Amount of Class I shares Consideration As of January 2, 2026 (number of shares finalized on January 22, 2026) 94,010 $ 2,369,086.96”

Tamboran Resources Corp issued 1,524,377 shares of Common Stock of common stock to PIPE Investors for $21.00 per share.

“pursuant to which such investors agreed to purchase an aggregate of 1,524,377 shares of common stock of the Company, par value $0.001 per shares (“Common Stock”) at a price of $21.00 per share upon the satisfaction of certain conditions, including, as applicable to certain of the PIPE Investors, approval by the Company’s stockholders. On January 13, 2026, the”

Anteris Technologies Global Corp. issued 15,652,173 shares of Common Stock of common stock to Covidien Group S.à r.l. for purchase price of $5.75 per PIPE Share.

“the Company agreed to issue and sell (the “Private Placement”) to the Investor 15,652,173 shares of Common Stock of the Company (the “PIPE Shares”) at a purchase price of $5.75 per PIPE Share.”

Stone Point Credit Income Fund issued 215,768.463 shares of common stock to select investors for $5,405,000.00 aggregate offering price.

“On January 1, 2026 (with the final number of shares being determined on January 21, 2026), the Fund issued and sold 215,768.463 of the Fund’s Common Shares, at NAV, pursuant to the subscription agreements entered into by the Fund and its investors, for an aggregate offering price of $5,405,000.00.”

Stone Point Credit Income Fund issued 2,035,928.144 shares of common stock to select investors for $51,000,000.00 aggregate offering price.

“Pursuant to a capital drawdown notice to select investors, Stone Point Credit Income Fund (the “Fund”) issued and sold 2,035,928.144 shares of the Fund’s common shares, par value $0.001 per share (the “Common Shares”), at a net asset value of $25.0500 (the “NAV”), on December 31, 2025, for an aggregate offering price of $51,000,000.00.”

EQT Private Equity Co LLC issued 1,976,793 of common stock to accredited investors (Regulation D) and/or non-U.S. investors (Regulation S) for $55,027,690.

“As of January 1, 2026, EQT Private Equity Company LLC (the “Company”) sold unregistered shares (the “Investor Shares”) of the Company to third-party investors for cash for aggregate consideration of approximately $55,027,690”

X3 Acquisition Corp. Ltd. issued 5,000,000 private warrants of warrant to the Sponsor for $1.00 per Private Warrant, generating total proceeds of $5,000,000.

“Simultaneously with the closing of the IPO, pursuant to the Private Placement Warrants Purchase Agreement, the Company consummated a private placement (the “Private Placement”) of an aggregate of 5,000,000 private warrants (the “Private Warrants”) to the Sponsor, at a price of $1.00 per Private Warrant, generating total proceeds of $5,000,000.”

Rithm Capital Corp. issued 11,500,000 shares of preferred stock for $25.00 per share.

“designate 11,500,000 shares of the Company’s authorized preferred stock as the 8.750% Series F Fixed-Rate Reset Cumulative Redeemable Preferred Stock, par value $0.01 per share, with a liquidation preference of $25.00 per share”

BridgeBio Pharma, Inc. issued convertible note to qualified institutional buyers for $632.5 million aggregate principal amount.

“BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers”

AEON Biopharma, Inc. issued warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share of warrant to Daewoong Pharmaceutical Co., LTD..

“(iii) warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share”

AEON Biopharma, Inc. issued $1,500,000 of convertible note to Daewoong Pharmaceutical Co., LTD..

“(ii) a new senior secured convertible note in a principal amount of $1,500,000 (the “New Note”)”

AEON Biopharma, Inc. issued 11,236,631 pre-funded warrants to purchase shares of Common Stock of warrant to Daewoong Pharmaceutical Co., LTD..

“on January 21, 2026, for the satisfaction in full of all obligations under the Old Notes, the Company issued to Daewoong (i) 11,918,380 newly issued shares of Common Stock and 11,236,631 pre-funded warrants to purchase shares of Common Stock (the “Exchange Shares”)”

AEON Biopharma, Inc. issued 11,918,380 newly issued shares of Common Stock of common stock to Daewoong Pharmaceutical Co., LTD..

“on January 21, 2026, for the satisfaction in full of all obligations under the Old Notes, the Company issued to Daewoong (i) 11,918,380 newly issued shares of Common Stock and 11,236,631 pre-funded warrants to purchase shares of Common Stock (the “Exchange Shares”)”

Perfect Moment Ltd. issued 11,458,306 shares of Common Stock of common stock to holders of Series AA Preferred for Automatic conversion of 924,921 shares of Series AA Preferred.

“Stock (the “Series AA Converted Shares”) to the holders (“Holders”) of Series AA Preferred. The Series AA Converted Shares were issued pursuant to the automatic conversion of 924,921 shares of Series AA Preferred, which constituted all issued and outstanding shares of Series AA Preferred. The Series AA Preferred was originally issued to the Holders pursuant to”

Perfect Moment Ltd. issued number of shares equal to difference between (i) 19.99% of number of shares of Common Stock outstanding as of closing date of conversion of Series AA Preferred of warrant to X3 Higher Moment Fund LLC for Issued as additional warrant without additional consideration.

“Additionally, the Company issued to X3 an additional warrant (“Warrant 2”, together with Amended Warrant 1, the “New Warrants”) to purchase up to an amount of shares of Common Stock (“Warrant 2 Shares”, together with the Warrant 1 Shares, the “Warrant Shares”) equal to the difference between (i) 19.99% of the number of shares of Common Stock of the Company outstanding as of the closing date of the conversion of the 12.00% Series AA Convertible Preferred Stock of the Company (“Series AA Preferred”) and (ii) the Securities.”

Perfect Moment Ltd. issued 3,204,908 shares of Common Stock underlying Warrant 1 of warrant to X3 Higher Moment Fund LLC for No additional consideration; modified warrant as part of Securities Purchase Agreement.

“As such, Warrant 1 has been amended and restated to provide for: (i) preemptive rights of X3 to participate in future financings by the Company, pro rata, except in connection with certain excluded issuances; (ii) the right of X3 to match any proposal to provide equity or debt financing to the Company so long as X3 holds at least 4.99% of the outstanding common stock of the Company; and (iii) weighted average anti-dilution price protection, with customary carve outs including for the excluded issuances (the foregoing, collectively, the “Amended Warrant 1”).”

Barings Private Credit Corp issued 5,098,618.965 unregistered shares of common stock to participating investors for aggregate consideration of approximately $103.9 million.

“pursuant to subscription agreements entered into with the participating investors for aggregate consideration of approximately $103.9 million”

ARES STRATEGIC INCOME FUND issued 4,011,672 of common stock to accredited investors for $110.2.

“sold Class I common shares of beneficial interest. The number of shares to be issued was finalized on January 21, 2026. The purchase price per Class I common share equaled the Fund’s net asset value (“NAV”) per Class I common share as of December 31, 2025. The offer and sale of these Class I common shares was exempt from the registration provisions of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof and/or Regulation S promulgated thereunder. The following table details the Class I common shares sold: Date of Unregistered Sales (dollar amount in millions) Amount of Class I Common Shares Total Consideration During January 2026 (number of shares finalized on January 21, 2026) 4,011,672 $ 110.2”

KKR FS Income Trust issued 1,943,114.120 Class I shares of common stock to participating investors for aggregate consideration of approximately $57.807 million.

“On January 2, 2026, KKR FS Income Trust (the “Company”) issued and sold 1,943,114.120 Class I shares (the “Class I Shares”) of the Company’s common shares of beneficial interest (the “Shares”) (with the final number of Class I Shares issued being determined on January 21, 2026) pursuant to subscription agreements entered into with the participating investors for aggregate consideration of approximately $57.807 million.”

enGene Therapeutics Inc. issued 40,850 2026 Warrants of warrant to Lenders (Hercules Capital, Inc. and others).

“On the Closing Date, the Company issued to the Lenders an aggregate number of 40,850 2026 Warrants reflecting each Lender’s pro rata commitments under the Amended Loan Agreement in connection with the 2026 Tranche 1 Advance (the “2026 Closing Date Warrants”).”

Ares Core Infrastructure Fund issued 11,395,800 of common stock to accredited investors for $285.4 million.

“In its monthly closing for January 2026, Ares Core Infrastructure Fund (the “Fund”) sold common shares of beneficial interest (“Common Shares”) for an aggregate purchase price of $285.4 million . The number of Common Shares to be issued was finalized on January 21, 2026.”

Remora Capital Corp issued 713,727.455 shares of common stock for at a price per share of $9.98 ... for an aggregate offering price of $7,123,000.

“On January 2, 2026, Remora Capital Corporation (the “Company”) issued 713,727.455 shares of common stock of the Company (the “Shares”), at a price per share of $9.98 (with the final number of shares being determined on January 20, 2026), for an aggregate offering price of $7,123,000.”

Ares Sports, Media & Entertainment Opportunities LP issued 386,532 Class A-I Units of unit to accredited investors and qualified purchasers for $10,489,100.

“Total Consideration Class S Units 3,701 $ 100,000 Class D Units 11,064 300,000 Class I Units 192,362 5,220,000 Class A-S Units 1,168,407 31,550,490 Class A-I Units 386,532 10,489,100 Total $ 47,659,590 ________________________________________ (1) The number of Units sold by the Fund was finalized on January 21, 2026, following the calculation of the respective”

Ares Sports, Media & Entertainment Opportunities LP issued 1,168,407 Class A-S Units of unit to accredited investors and qualified purchasers for $31,550,490.

“the Fund: Class Number of Units Sold(1) Total Consideration Class S Units 3,701 $ 100,000 Class D Units 11,064 300,000 Class I Units 192,362 5,220,000 Class A-S Units 1,168,407 31,550,490 Class A-I Units 386,532 10,489,100 Total $ 47,659,590 ________________________________________ (1) The number of Units sold by the Fund was finalized on January 21, 2026,”

Ares Sports, Media & Entertainment Opportunities LP issued 192,362 Class I Units of unit to accredited investors and qualified purchasers for $5,220,000.

“table details the Units sold by the Fund: Class Number of Units Sold(1) Total Consideration Class S Units 3,701 $ 100,000 Class D Units 11,064 300,000 Class I Units 192,362 5,220,000 Class A-S Units 1,168,407 31,550,490 Class A-I Units 386,532 10,489,100 Total $ 47,659,590 ________________________________________ (1) The number of Units sold by the Fund was”

Ares Sports, Media & Entertainment Opportunities LP issued 11,064 Class D Units of unit to accredited investors and qualified purchasers for $300,000.

“$47.7 million. The following table details the Units sold by the Fund: Class Number of Units Sold(1) Total Consideration Class S Units 3,701 $ 100,000 Class D Units 11,064 300,000 Class I Units 192,362 5,220,000 Class A-S Units 1,168,407 31,550,490 Class A-I Units 386,532 10,489,100 Total $ 47,659,590 ________________________________________ (1) The number”

Ares Sports, Media & Entertainment Opportunities LP issued 3,701 Class S Units of unit to accredited investors and qualified purchasers for $100,000.

“consideration of approximately $47.7 million. The following table details the Units sold by the Fund: Class Number of Units Sold(1) Total Consideration Class S Units 3,701 $ 100,000 Class D Units 11,064 300,000 Class I Units 192,362 5,220,000 Class A-S Units 1,168,407 31,550,490 Class A-I Units 386,532 10,489,100 Total $ 47,659,590”

Blue Owl Digital Infrastructure Trust issued 6,883,622 of its common shares of common stock to accredited investors for gross proceeds of approximately $69.6 million.

“On January 2, 2026, Blue Owl Digital Infrastructure Trust (the “ Company ”) sold an aggregate of 6,883,622 of its common shares (with the final number of shares being determined on January 16, 2026) for gross proceeds of approximately $69.6 million”

URBAN ONE, INC. issued common stock.

“The reverse stock split is expected to become effective at 11:59 p.m. on January 22, 2026 (the “Effective Date”).”

Beyond Air, Inc. issued up to 3,930,818 shares of Common Stock of warrant to an institutional investor for aggregate gross proceeds under the Purchase Agreement of $5,000,000.

“warrants to purchase up to 3,930,818 shares of Common Stock (the “Common Warrants”, and together with the Pre-funded Warrants the “Warrants”), for aggregate gross proceeds under the Purchase Agreement of $5,000,000”

Beyond Air, Inc. issued up to 3,405,828 shares of Common Stock of warrant to an institutional investor for $1.2719 per Pre-funded Warrant.

“pre-funded warrants to purchase up to 3,405,828 shares of Common Stock (the “Pre-funded Warrants”) at a purchase price of $1.2719 per Pre-funded Warrant”

Beyond Air, Inc. issued 524,990 shares of common stock to an institutional investor for $1.272 per Share.

“the Company agreed to sell to the investor, and the investor agreed to purchase from the Company, in a private placement offering, an aggregate of (i) 524,990 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $1.272 per Share”

Blackstone Real Estate Income Trust, Inc. issued 234,941 of common stock to a feeder vehicle primarily created to hold the Company's Class I common stock and Class C common stock, which in turn offers interests in itself to certain non-U.S. persons for $3,812,371.

“On January 14, 2026, Blackstone Real Estate Income Trust, Inc., a Maryland corporation (the “Company”), sold unregistered shares (the “Shares”) of the Company’s Class C common stock to a feeder vehicle primarily created to hold the Company's Class I common stock and Class C common stock, which in turn offers interests in itself to certain non-U.S. persons. The offer and sale of the Shares was exempt from the registration provisions of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) and Regulation S thereunder. The following table details the Shares sold to such feeder vehicle: Date of Unregistered Sale Number of Class C Common Shares Issued to Feeder Vehicle Consideration January 14, 2026 234,941 $3,812,371”

Vivos Therapeutics, Inc. issued 138,765 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC.

“issued to Wainwright or its designees warrants to purchase 138,765 shares of Common Stock representing 7.0% of the shares of Common Stock underlying the Inducement Warrants”

Vivos Therapeutics, Inc. issued up to 1,982,356 shares of Common Stock of warrant to an institutional investor.

“a five-year, Series A Common Stock Purchase Warrant to purchase up to 1,982,356 shares of Common Stock at an exercise price of $2.09 per share”

ExchangeRight Income Fund issued 34,447 of its Class ER-A Common Shares of common stock for Gross Proceeds $1,000,000.

“506(c) of Regulation D promulgated thereunder. The following table details the shares sold: Number of Gross Share Class Shares Sold Proceeds * Class ER-A Common Shares 34,447 $ 1,000,000 * Includes selling commissions described above. Forward-Looking Statements Certain statements contained in this Current Report on Form 8-K other than historical facts may be”

BITMINE IMMERSION TECHNOLOGIES, INC. issued increase from 500,000,000 shares to 50,000,000,000 shares of common stock.

“Item 3.03. Material Modification to Rights of Security Holders. On January 15, 2026, Bitmine Immersion Technologies, Inc. (the “ Company ”) held its annual meeting of stockholders (the “ Annual Meeting ”). At the Annual Meeting, as described below under Item 5.07, the stockholders of the Company, among other things, approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”) to increase the total number of shares of common stock (the “ Common Stock ”) the Company is authorized to issue from 500,000,000 shares to 50,000,000,000 shares (the “ Charter Amendment ”).”

VEEA INC. issued Warrant to purchase 990,099 shares of Common Stock of warrant to White Lion Capital, LLC for cash proceeds of $475,000, net of original issuance discount and certain transaction expenses.

“purchase 990,099 shares of Common Stock (the “ Warrant Shares ”) with an exercise price of $0.505 per share. At the First Closing, the Company received cash proceeds of $475,000, net of original issuance discount and certain transaction expenses. The Convertible Notes mature 12-months from the date of issuance and accrue interest at an annual rate of five”

VEEA INC. issued Convertible Note with a face amount of $555,556 of convertible note to White Lion Capital, LLC for cash proceeds of $475,000, net of original issuance discount and certain transaction expenses.

“purchase 990,099 shares of Common Stock (the “ Warrant Shares ”) with an exercise price of $0.505 per share. At the First Closing, the Company received cash proceeds of $475,000, net of original issuance discount and certain transaction expenses. The Convertible Notes mature 12-months from the date of issuance and accrue interest at an annual rate of five”

INSPIRE VETERINARY PARTNERS, INC. issued 2,500,000 shares of common stock to Target Capital 1 LLC.

“the Company and Target agreed to cancel $25,000 of the outstanding principal amount under that certain promissory note issued by the Company to Target on June 10, 2025, as amended (the “June Note”), in exchange for 2,500,000 shares of the Company’s Class A common stock”

North Haven Net REIT issued 30,392 Class I shares of common stock to a feeder vehicle primarily created to hold certain classes of the Company's common shares for aggregate consideration of approximately $623,000.

“As of January 2, 2026, North Haven Net REIT, a Maryland statutory trust (the “Company”), sold an aggregate of 30,392 Class I shares (the "Shares") (with the final number of Shares being determined on January 15, 2026) for aggregate consideration of approximately $623,000, based on the net asset value per share as of December 31, 2025, to a feeder vehicle primarily created to hold certain classes of the Company's common shares.”

Wellgistics Health, Inc. issued warrant to Placement Agent and its designees for 5% of aggregate gross proceeds.

“the Company issued common stock purchase warrants, in the form filed as Exhibit 10.2 to this Current Report on Form 8-K (the “PA Warrants”) to the Placement Agent and its designees to purchase a number of shares of Company common stock equal to 5% of the aggregate gross proceeds received by the Company with an exercise price equal to the closing price of the common stock on the last trading day before closing of the Offering.”

Wellgistics Health, Inc. issued convertible note to certain investors (the "Investors") for up to $8,125,000 in aggregate principal amount; aggregate purchase price of $6,500,000.

“On January 16, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $8,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of secured convertible promissory notes (the “Notes”) (the “Offering”).”

Infinite Eagle Acquisition Corp. issued 350,000 Class A Ordinary Shares of common stock to Eagle Equity Partners VI, LLC (the Sponsor) for at the initial public offering price of $10.00 per share (for an aggregate purchase price of $3,500,000).

“Simultaneously with the closing of the IPO, pursuant to the Private Placement Shares Purchase Agreement, the Company completed the private sale of 350,000 Class A Ordinary Shares (the “Private Placement Shares”) at the initial public offering price of $10.00 per share (for an aggregate purchase price of $3,500,000).”

AGENUS INC issued 2,133,333 shares of common stock to Zynext Ventures USA LLC for $16.0 million ($7.50/share).

“Agreement (the “SPA”), pursuant to which Zynext agreed to purchase 2,133,333 shares of the Company’s common stock (the “Shares”) for an aggregate purchase price of approximately $16.0 million, or $7.50 per share. On January 15, 2026, the transactions contemplated by the SPA closed. The foregoing description of the SPA does not purport to be complete and is qualified”

ABVC BIOPHARMA, INC. issued an aggregate of 1,500,250 shares of the Company’s common stock of common stock to accredited investors and Non-U.S. Persons for aggregate amount of $2,275,468.

“the Company’s chairman for the maximum time permitted by law. Between May 26, 2025, and January 6, 2026, the Company accepted additional subscriptions in the aggregate amount of $2,275,468 on the same terms and conditions as the Reg S Offering (the “ Additional Subscriptions ”); the Company’s Board of Directors approved the Additional Subscriptions on January 12,”

ABVC BIOPHARMA, INC. issued an aggregate of 1,987,557 shares of common stock to 43 Non-U.S. Persons for aggregate gross proceeds of approximately $1,289,750.

“the Company sold an aggregate of 1,987,557 shares (the “ Shares ”) of its Common Stock to 43 Non-U.S. Persons (as defined in Regulation S under the Securities Act). The offer and sale of the Shares was exempt from the registration provisions of the Securities Act, pursuant to Regulation S thereunder (“ Regulation S ”); the Company received aggregate gross proceeds of approximately $1,289,750 for the Shares”

Clean Energy Technologies, Inc. issued 1,932,000 shares of Company common stock of common stock to Filled Converge Limited and Li Xiaoguang for US$700,000 equivalent in HK$ (the "Cash Purchase Price") and 1,932,000 shares of Company common stock.

“amount of HK$356,375,000 issued by China Ruifeng Renewable Energy Holdings Limited, a Hong Kong listed company with the ticker “527.HK,” for a purchase price consisting of US$700,000 equivalent in HK$ (the “ Cash Purchase Price ”) and 1,932,000 shares of Company common stock (the “ Shares ”). $500,000 of the Cash Purchase Price shall be paid at closing, and”

Stablecoin Development Corp issued 837,696,130 shares of Common Stock underlying pre-funded warrants of warrant to R01 Fund LP, Framework Ventures IV L.P., Tether Investments, S.A. de C.V. and Sky Frontier Foundation for aggregate gross proceeds of approximately $134 million.

“On January 16, 2026, NovaBay Pharmaceuticals, Inc. (the “Company”), entered into a Securities Purchase Agreement (the “SPA”) with each of R01 Fund LP, Framework Ventures IV L.P., Tether Investments, S.A. de C.V. and Sky Frontier Foundation (together, the “Purchasers”). Pursuant to the SPA, the Company issued and sold pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 837,696,130 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) for aggregate gross proceeds of approximately $134 million.”

Vivakor, Inc. issued 11,904,762 shares of common stock to J.J. Astor & Co. for $50,000 of the Principal Amount.

“On January 12, 2026, the Company received a Notice of Conversion from the Lender converting $50,000 of the Principal Amount of the Second Note into 11,904,762 shares of the Company’s common stock”